JPRN-UMIN000009562Completed未知
Evaluation of the efficacy and safety for switching from premixed insulin to ultra-long acting insulin plus ultra-rapid insulin - Evaluation of the efficacy and safety for ultra-long acting insulin plus ultra-rapid insulin
Department of Endocrinology and Metabolism, Nagoya City West Medical Center0 sites40 target enrollmentStarted: December 17, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.patients who need insulin therapy newly during this study 2.patients who have allergy for insulin glargine or glulisine 3.patients who had suffered from severe ketosis and diabetic coma or pre-coma 4.patients with serious infection, inflammation, or injury pre- or post- operative state 5.patients who are pregnant, hope to be pregnant, or are in lactation period 6.patients had suffered from drug-induced muscle disorder 7.drug abuser or heavy alcohol drinker
Investigators
Similar Trials
Completed
Not Applicable
Investigation of efficacy and safety of switching from basal-bolus therapy to combination therapy with GLP-1 receptor agonist and basal insulin injection in type 2 diabetestype 2 diabetesJPRN-UMIN000013222Juntendo University Graduate School of Medicine30
Not yet recruiting
Unknown
Study of the effectiveness and safety of switching from JAK inhibitors to non-TNF biologics in elderly patients with rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000050387Kawasaki Medical School30
Completed
Not Applicable
Prospective study of effecacy and safety of switch from oral medicine of tramadolto fentanyl sticking medicine (dyuroteppu MT patch on the 3rd) in lung cancer and malignant pleura mesothelioma with the pailung cancer, malignant mesotheliomaJPRN-UMIN000005620Osaka Prefectural Medical Center for Respiratory and Allergic Diseases15
Active, not recruiting
Phase 1
Assessing the safety and efficacy of switching to Azarga (Brinzolamide/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure - not applicableEUCTR2009-015795-10-SIAlcon d.o.o.120
Recruiting
Phase 1
Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)HIV-1MedDRA version: 20.1Level: LLTClassification code: 10020172Term: HIV infection NOS Class: 10021881CTIS2023-504192-25-00EAT ID Foundation60